Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pacira BioSciences, Inc. - Common Stock
(NQ:
PCRX
)
26.51
+0.49 (+1.88%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pacira BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
December 18, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
December 02, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
November 26, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
November 11, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
November 06, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
November 05, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
November 04, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
October 30, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
October 28, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
October 27, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
October 23, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
October 21, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
October 20, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Second Quarter 2025 Financial Results
August 05, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
July 24, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
July 22, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Lifshitz Law PLLC Announces Investigations of Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), ModivCare, Inc. (NASDAQ: MODV), and Integral Ad Science Holding Corp. (NASDAQ: IAS)
June 23, 2025
Via
ACCESS Newswire
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
June 18, 2025
From
Pacira BioSciences
Via
GlobeNewswire
PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
June 17, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Lifshitz Law PLLC Announces Investigations of DMC Global Inc. (NASDAQ: BOOM), Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), and ModivCare, Inc. (NASDAQ: MODV)
June 16, 2025
Via
ACCESS Newswire
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
June 11, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
May 26, 2025
From
Grabar Law Office
Via
GlobeNewswire
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
May 15, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
May 14, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports First Quarter 2025 Financial Results
May 08, 2025
From
Pacira BioSciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
